Press Releases
Press Releases
Bristol-Myers Squibb Company and Pfizer Inc.announced that the ADVANCE-3 study results
Bristol-Myers Squibb Company and Pfizer Inc.announced that the ADVANCE-3 study results, published in The New England Journal of Medicine, showed apixaban was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients...
Press Releases
Novartis drug Tasigna approved in Japan for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
Novartis has received approval from Japan's Ministry of Health, Labour and Welfare to offer Tasigna® (nilotinib) as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The...
Press Releases
Lilly Announces Completion of Avid Acquisition and FDA Priority Review for florbetapir
Eli Lilly and Company announced that it has completed the acquisition of Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases. The transaction, first announced on...
Press Releases
Merck KGaA and sanofi-aventis Sign Agreement to Jointly Investigate Novel Combinations Against Cancer
Merck KGaA announced today that it has signed a worldwide research and development agreement with sanofi-aventis U.S. Inc., under which its division Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block...
Press Releases
Malaria Vaccine Initiative, Merck and NYU Langone Medical Center Collaborate to Research Potential Malaria Vaccine
Development of a vaccine to prevent the malaria parasite from entering the human liver is the goal of a new collaboration announced by global leaders in malaria research and vaccine development. The PATH Malaria Vaccine Initiative (MVI), Merck (known...
Press Releases
New subgroup analysis of the LUX-Lung 1 trial suggests benefit from afatinib in lung cancer patients
New data to be presented show that afatinib (BIBW 2992) leads to a significant four-fold extension (4.4 months vs. 1 month for placebo) in progression-free survival, - the time before a tumour starts to grow again- , for lung...
Press Releases
The R and D Leaders Band Together at Discovery Summit 2011 to Uncover Innovative Solutions
The Discovery Summit 2011, presented by marcus evans, will be taking place from 21-23 March 2011 in Cannes, France. Confronted by compound challenges the global pharmaceutical scenario needs to redefine its industry dynamics and diversify its global vision. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read